Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.70 |
| ▸ | DDB1 | Q16531 | 18/20 | 0.70 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.70 |
| ▸ | TNF | P01375 | 1/20 | 0.70 |
| ▸ | IL1B | P01584 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26764344 | 1.00 | CRBN (0.70) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL282871 | 1.00 | CRBN (0.70) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL29442254 | 0.88 | CRBN (0.54) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL29442250 | 0.88 | CRBN (0.54) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL15945432 | 0.88 | CRBN (0.54) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL15945434 | 0.88 | CRBN (0.54) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL26672081 | 0.88 | CRBN (0.53) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL20456410 | 0.86 | CRBN (0.52) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL283184 | 0.85 | CRBN (0.79) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL283314 | 0.85 | CRBN (0.79) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4646407-A1 | SOLID FORMS AND METHODS OF USE | Salarius Pharmaceuticals, Inc (US) | 2025-11-12 | — | — | EP | disclosed |
| CN-109153644-B | Small molecules against CEREBLON to enhance effector T cell function | H·李·莫菲特癌症中心研究有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-108350062-B | Targeted protein degradation to attenuate adverse inflammatory responses associated with adoptive T cell therapy | 达纳-法伯癌症研究所股份有限公司 | 2022-10-14 | — | — | CN | disclosed |